Felix Baker - Net Worth and Insider Trading

Felix Baker Net Worth

The estimated net worth of Felix Baker is at least $10.1 Billion dollars as of 2024-03-28. Felix Baker is the Director, 10% Owner of Seagen Inc and owns about 40,992,596 shares of Seagen Inc (SGEN) stock worth over $9.4 Billion. Felix Baker is the Director, 10% Owner of Genomic Health Inc and owns about 11,841,478 shares of Genomic Health Inc (GHDX) stock worth over $751 Million. Felix Baker is also the Director, 10% Owner of ACADIA Pharmaceuticals Inc and owns about 440,802 shares of ACADIA Pharmaceuticals Inc (ACAD) stock worth over $8 Million. Besides these, Felix Baker also holds Mirati Therapeutics Inc (MRTX) , BioCryst Pharmaceuticals Inc (BCRX) . Details can be seen in Felix Baker's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Felix Baker has not made any transactions after 2016-11-08 and currently still holds the listed stock(s).

Transaction Summary of Felix Baker

To

Felix Baker Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Felix Baker owns 31 companies in total, including IGM Biosciences Inc () , Incyte Corp () , and Kodiak Sciences Inc () among others .

Click here to see the complete history of Felix Baker’s form 4 insider trades.

Insider Ownership Summary of Felix Baker

Ticker Comapny Transaction Date Type of Owner
IGM Biosciences Inc 2022-03-12 director & 10 percent owner
Incyte Corp 2008-01-04 director & 10 percent owner
Kodiak Sciences Inc 2022-01-21 director & 10 percent owner
Prelude Therapeutics Inc 2022-06-17 director & 10 percent owner
Kiniksa Pharmaceuticals Ltd 2022-06-29 director
Atreca Inc 2023-10-19 other: Former 10% Owner
BeiGene Ltd 2016-02-02 director & 10 percent owner
ACADIA Pharmaceuticals Inc 2013-06-05 10 percent owner
Seagen Inc 2020-12-31 director & 10 percent owner
Alexion Pharmaceuticals Inc 2020-05-14 director
Zymeworks Inc 2020-03-16 director
Neoleukin Therapeutics Inc 2015-08-07 10 percent owner
Aceragen Inc 2006-03-24 10 percent owner
HOOKIPA Pharma Inc 2019-04-17 10 percent owner
Principia Biopharma Inc 2018-09-13 10 percent owner
Invitae Corp 2015-08-27 10 percent owner
Bellicum Pharmaceuticals Inc 2015-12-24 10 percent owner
Mirati Therapeutics Inc 2013-10-24 10 percent owner
Rhythm Pharmaceuticals Inc 2017-10-04 10 percent owner
BioCryst Pharmaceuticals Inc 2013-08-01 10 percent owner
Intellia Therapeutics Inc 2016-05-05 10 percent owner
XOMA Corp 2012-03-06 10 percent owner
Ocera Therapeutics Inc 2012-03-12 10 percent owner
Heron Therapeutics Inc 2009-10-19 10 percent owner
XOMA Corp 2012-03-06 10 percent owner
Talis Biomedical Corp 2022-06-10 director & 10 percent owner
DBV Technologies SA 2022-06-13 director & 10 percent owner
Spyre Therapeutics Inc 2021-02-23 director
Entrada Therapeutics Inc 2022-05-16 10 percent owner
TScan Therapeutics Inc 2022-05-10 director & 10 percent owner
Madrigal Pharmaceuticals Inc 2023-06-15 director

Felix Baker Latest Holdings Summary

Felix Baker currently owns a total of 5 stocks. Among these stocks, Felix Baker owns 40,992,596 shares of Seagen Inc (SGEN) as of November 8, 2016, with a value of $9.4 Billion and a weighting of 92.49%. Felix Baker owns 11,841,478 shares of Genomic Health Inc (GHDX) as of August 15, 2016, with a value of $751 Million and a weighting of 7.41%. Felix Baker also owns 440,802 shares of ACADIA Pharmaceuticals Inc (ACAD) as of June 5, 2013, with a value of $8 Million and a weighting of 0.08%. The other 2 stocks Mirati Therapeutics Inc (MRTX) , BioCryst Pharmaceuticals Inc (BCRX) have a combined weighting of 0.02% among all his current holdings.

Latest Holdings of Felix Baker

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
SGEN Seagen Inc 2016-11-08 40,992,596 228.74 9,376,646,409
GHDX Genomic Health Inc 2016-08-15 11,841,478 63.44 751,223,364
ACAD ACADIA Pharmaceuticals Inc 2013-06-05 440,802 18.20 8,022,596
MRTX Mirati Therapeutics Inc 2013-10-24 40,308 58.70 2,366,080
BCRX BioCryst Pharmaceuticals Inc 2013-08-01 28,361 5.15 146,059

Holding Weightings of Felix Baker


Felix Baker Form 4 Trading Tracker

According to the SEC Form 4 filings, Felix Baker has made a total of 0 transactions in Seagen Inc (SGEN) over the past 5 years. The most-recent trade in Seagen Inc is the acquisition of 382,500 shares on November 8, 2016, which cost Felix Baker around $23 Million.

According to the SEC Form 4 filings, Felix Baker has made a total of 0 transactions in Genomic Health Inc (GHDX) over the past 5 years. The most-recent trade in Genomic Health Inc is the acquisition of 100,000 shares on August 15, 2016, which cost Felix Baker around $3 Million.

According to the SEC Form 4 filings, Felix Baker has made a total of 0 transactions in ACADIA Pharmaceuticals Inc (ACAD) over the past 5 years. The most-recent trade in ACADIA Pharmaceuticals Inc is the acquisition of 2,340,314 shares on June 5, 2013, which cost Felix Baker around $34 Million.

More details on Felix Baker's insider transactions can be found in the Insider Trading History of Felix Baker table.

Insider Trading History of Felix Baker

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Felix Baker Trading Performance

GuruFocus tracks the stock performance after each of Felix Baker's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Felix Baker is 10.96%. GuruFocus also compares Felix Baker's trading performance to market benchmark return within the same time period. The performance of stocks bought by Felix Baker within 3 months outperforms 22 times out of 37 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Felix Baker's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Felix Baker

Average Relative Return

29.84%

Average relative return per transaction

Outperforming Transactions

62%

23 out of 37 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Relative Return(%) 5.58 10.96 22.87 29.84 19.2 11.31
Relative Return to S&P 500(%) 4.36 7.52 14.59 14.11 4.67 0.94

Felix Baker Ownership Network

Ownership Network List of Felix Baker

No Data

Ownership Network Relation of Felix Baker


Felix Baker Owned Company Details

What does IGM Biosciences Inc do?

Who are the key executives at IGM Biosciences Inc?

Felix Baker is the director & 10 percent owner of IGM Biosciences Inc. Other key executives at IGM Biosciences Inc include Principal Accounting Officer Steven Weber , Chief Medical Officer Chris H Takimoto , and Chief Financial Officer Misbah Tahir .

IGM Biosciences Inc () Insider Trades Summary

Over the past 18 months, Felix Baker made no insider transaction in IGM Biosciences Inc (). Other recent insider transactions involving IGM Biosciences Inc () include a net sale of 45,975 shares made by Bruce Keyt , a net sale of 11,918 shares made by George Gauthier , and a net sale of 14,987 shares made by Lisa Lynn Decker .

In summary, during the past 3 months, insiders sold 28,125 shares of IGM Biosciences Inc () in total and bought 0 shares, with a net sale of 28,125 shares. During the past 18 months, 229,745 shares of IGM Biosciences Inc () were sold and 795,616 shares were bought by its insiders, resulting in a net purchase of 565,871 shares.

IGM Biosciences Inc ()'s detailed insider trading history can be found in Insider Trading Tracker table.

To

IGM Biosciences Inc Insider Transactions

No Available Data

Felix Baker Mailing Address

Above is the net worth, insider trading, and ownership report for Felix Baker. You might contact Felix Baker via mailing address: Baker Bros. Advisors Lp, 860 Washington Street 3rd Floor, New York Ny 10014.

Discussions on Felix Baker

No discussions yet.